Illumina appoints Eli Lilly's CSO Daniel Skovronsky to Board effective June 16, 2026

ILLUMINA, INC.

Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board effective June 16, 2026; Board expanded to 10 members.
Skovronsky is Eli Lilly's Chief Scientific and Product Officer and President of Lilly Research Laboratories.
He brings expertise in drug discovery, clinical development, and translational medicine to Illumina's genomics focus.
Skovronsky will participate in the standard non-employee director compensation program described in April 9, 2026 proxy.
He qualifies as an independent director under Nasdaq and SEC rules; will stand for election at 2027 annual meeting.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel M. Skovronsky

Director

ILMN · ILLUMINA, INC.

Effective: 2026-06-16
Filed: June 23, 2026, 9:08 AM ET

On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel M. Skovronsky was appointed as Director at ILLUMINA, INC..

Action: appointed
Role: Director

Exact text from the filing

On June 16, 2026, the Board of Directors (the “Board”) of Illumina, Inc. (the “Company”) increased the size of the Board from nine to ten members and appointed Daniel M. Skovronsky, M.D., Ph.D., to serve on the Board, effective immediately.

View on SEC.gov

ILLUMINA, INC. filing history →

Source: SEC EDGAR

accession 0001110803-26-000138

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.